Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.83 |
| ▸ | PIK3R2 | O00459 | 20/20 | 0.83 |
| ▸ | PIK3CA | P42336 | 20/20 | 0.83 |
| ▸ | PIK3CB | P42338 | 20/20 | 0.83 |
| ▸ | PIK3CG | P48736 | 20/20 | 0.83 |
| ▸ | PIK3R5 | Q8WYR1 | 20/20 | 0.83 |
| ▸ | PIK3R3 | Q92569 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30443259 | 1.00 | PIK3CD (0.83) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL25883968 | 0.94 | PIK3CD (0.73) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL25224836 | 0.93 | PIK3CD (0.72) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL25230907 | 0.92 | PIK3CD (0.69) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL30442599 | 0.92 | PIK3CD (0.69) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL25226695 | 0.91 | PIK3CD (0.68) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL30443090 | 0.91 | PIK3CD (0.68) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| Roginolisib SCHEMBL29515379 | 0.91 | PIK3CD (1.00) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| Roginolisib SCHEMBL12849 | 0.91 | PIK3CD (1.00) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL25236903 | 0.91 | PIK3CD (0.68) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-4190789-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885PIK3R2 12/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.